このエントリーをはてなブックマークに追加
ID 49384
FullText URL
Thumnail 125_47.pdf 882 KB
Title Alternative
A case of metastatic cecal cancer with mutation in the BRAF oncogene and poor survival
Author
Inada, Ryo
Takehara, Kiyoto
Sugihara, Masahiro
Mori, Yoshiko
Kubota, Nobuhito
Morikawa, Tatsuya
Uno, Futoshi
Sadamori, Yu
Abstract
 A 79-year-old woman visited a previous hospital with a complaint of general fatigue. The patient was diagnosed with cecal cancer with multiple liver metastases and lymph node metastases on colonoscopy, abdominal ultrasonography and CT scan, and was referred to our division for treatment. Based on the diagnosis of non-curative colonic cancer, we planned to perform systematic chemotherapy after local surgical treatment. We performed an ileocecal resection, and the specimen showed poorly differentiated adenocarcinoma with mutation in the BRAF oncogene. After the surgical treatment, the tumor grew rapidly and the patient died from cancer on the 19th postoperative day without having the opportunity to undergo chemotherapy.  Multiple genetic and epigenetic alterations in oncogenes and tumor suppressor genes are involved in the process of colorectal carcinogenesis. Some of the alterations have been identified as predictive and prognostic biomarkers. A mutation in the BRAF oncogene was reported to be associated with a very unfavorable prognosis in colorectal cancers. Some of the cases with rapid progression are suggested to have the BRAF oncogene mutation. According to our experience, chemotherapy before surgical treatment might improve the prognosis of cases with the BRAF mutation.
Keywords
大腸癌(colorectal cancer)
BRAF変異(BRAF mutation)
化学療法(chemotherapy)
分子標的薬(molecular target therapy)
Note
症例報告(Case Report)
Published Date
2013-04-01
Publication Title
岡山医学会雑誌
Publication Title Alternative
Journal of Okayama Medical Association
Volume
volume125
Issue
issue1
Publisher
岡山医学会
Publisher Alternative
Okayama Medical Association
Start Page
47
End Page
50
ISSN
0030-1558
NCID
AN00032489
Content Type
Journal Article
Related Url
http://www.okayama-u.ac.jp/user/oma/
References
1) Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, et al. : Mutations of the BRAF gene in human cancer. Nature (2002) 417, 949-954.
2) Downward J : Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 3, 11-22.
3) Wong JJ, Hawkins NJ, Ward RL : Colorectal cancer : a model for epigenetic tumorigenesis. Gut (2007) 56, 140-148.
4) Tol J, Nagtegaal ID, Punt CJ : BRAF mutation in metastatic colorectal cancer. N Engl J Med (2009) 361, 98-99.
5) Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, Kambara T, MacPhee DG, Young J, Leggett BA, Jass JR, Tanaka N, et al. : Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol (2004) 22, 4584-4594.
6) Nagasaka T, Koi M, Kloor M, Gebert J, Vilkin A, Nishida N, Shin SK, Sasamoto H, Tanaka N, Matsubara N, Boland CR, Goel A : Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology (2008) 134, 1950-1960.
7) Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS : BRAF(E600) in benign and malignant human tumours. Oncogene (2008) 27, 877-895.
8) Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, et al. : Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol (2009) 27, 5924-5930.
9) Rebersek M, Boc M, Cerkovnik P, Benedik J, Hlebanja Z, Volk N, Novakovic S, Ocvirk J : Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis. Radiol Oncol (2011) 45, 285-291.
10) 永坂岳司, 母里淑子, 楳田祐三,藤原俊義 : がんのバイオマーカー, 大腸癌. 日本臨床(2011)70, 802-808.
11) Cancer Genome Atlas Network : Comprehensive molecular portraits of human breast tumours. Nature (2012) 490, 61-70.
12) Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P : Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol (2011) 29, 1261-1270.
13) 松田明久, 古川清憲, 高崎秀明, 鈴木英之, 菅 隼人, 鶴田宏之, 松本智司, 進士誠一, 田尻 孝 : stage Ⅳ大腸癌における予後因子の臨床病理学的検討. 日消外会誌(2006)39, 529-535.
14) 大腸癌治療ガイドライン―医師用, 大腸癌研究会編, 金原出版株式会社, 東京(2010)pp16-17.
15) Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, et al. : Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer : updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 29, 2011-2019.
language
日本語
Copyright Holders
Copyright (c) 2013 岡山医学会
File Version
publisher
Refereed
True
DOI
Eprints Journal Name
joma